Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$211.17 USD

211.17
2,255,897

-16.27 (-7.15%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug

The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session.

Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan

Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.

Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?

Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.

Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know

Biogen Inc. (BIIB) closed at $288.08 in the latest trading session, marking a +1.07% move from the prior day.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe

Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed at $274.72 in the latest trading session, marking a -1.62% move from the prior day.

Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's

FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.

Should iShares Morningstar MidCap Value ETF (IMCV) Be on Your Investing Radar?

Style Box ETF report for IMCV

Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device

Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed at $272.63 in the latest trading session, marking a -1.55% move from the prior day.

Biogen Inc. (BIIB) Stock Moves -0.27%: What You Should Know

Biogen Inc. (BIIB) closed at $274.04 in the latest trading session, marking a -0.27% move from the prior day.

Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma

Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma.

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Biogen Inc. (BIIB) closed at $286.86 in the latest trading session, marking a -0.23% move from the prior day.

Biogen Inc. (BIIB) Stock Moves -1.94%: What You Should Know

Biogen Inc. (BIIB) closed at $283.44 in the latest trading session, marking a -1.94% move from the prior day.

Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines

Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $285.37, moving -1.29% from the previous trading session.

Entrada (TRDA) Surges on Collaboration With Vertex for DMI

Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.

BIIB vs. TECH: Which Stock Is the Better Value Option?

BIIB vs. TECH: Which Stock Is the Better Value Option?

Novartis' (NVS) PNH Candidate Achieves Study Objectives

Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.

Why Is Mirati (MRTX) Down 19.9% Since Last Earnings Report?

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion (ESPR) Reports Positive Data From CLEAR Study

Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.

Is Biogen (BIIB) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.